[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysglycemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysglycemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,82,120,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644539","perioperative-use-of-continuous-glucose-monitoring-for-scheduled-cesarean-deliveries-peruse-100644539",false,"NCT07671599","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study","PERUSE","Inclusion Criteria:\n\n* singleton pregnancy\n* no prior diagnosis of diabetes (gestational included)\n* scheduled term cesarean delivery in Mount Sinai Health System\n* aged 18-50 years\n\nExclusion Criteria:\n\n* preexisting diabetes mellitus\n* diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening\n* known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.)\n* use of antenatal steroids within the two weeks prior to delivery","ALL","18 Years","50 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.",[26],"Dysglycemia","NOT_YET_RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":22},"2026-09",{"date":35,"type":22},"2028-05",{"name":37,"class":38},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100628619","effects-of-habitual-water-intake-on-thirst-in-healthy-young-adults-explained-by-osmoadaptive-metabolism-brain-and-kidney-function-adapt-thirst-100628619","NCT07464002","Effects of Habitual Water Intake on Thirst in Healthy Young Adults Explained by Osmoadaptive Metabolism, Brain and Kidney Function (Adapt-Thirst)","Studie Zum Habituellen Durst Und Adapt Durst Studie: Habitual Thirst Study and Adapt Thirst Study","Adapt-Thirst","All randomized participants must have complete data from 4 weeks of screening. All inclusion criteria below must be met:\n\n* 4 weeks of 3-day mean total water intake of 35 ml\u002Fkg body weight\n* 4 weeks of \\\u003C1L\u002Fd drinking water\n* 4 weeks of \\\u003C1 hr\u002Fd moderate or vigorous physical activity given daily life conditions in Salzburg, Austria\n* No history of chronic disease\n* Normal blood pressure,\n* Normal blood chemistry and complete blood count (CBC) test results\n* Normal overnight urine concentration, and normal acute urine dilution after 500mL drinking water\n* Normal weight and height between 160-170 cm for women and 175-185 cm for men)\n* After overnight food and water restriction urine osmolality above 800 mmol\u002Fkg, salivary osmolality above 100 mmol\u002Fkg, and a thirst score below 70 mm on a 100 mm visual analog scale.\n\nExclusion Criteria:\n\n* Individuals will be excluded from participation if the gender-specific target numbers have already been reached\n* Perceived stress score of \\> 20 at any time during Weeks 1-4\n\n  * Schedule that does not allow continuous study participation\n  * Intention to spend more than a day outside the Salzburg area during the study period (to reduce exposure to ground water with different background D2O as potential source of error)\n* Headache within the last six months\n* Pregnant, planning a pregnancy, or irregular or unknown menstrual cycle\n\n  * Active use of tobacco or e-cigarettes\n  * Daily consumption of alcohol\n  * Regular use of medication\n  * Agoraphobia or claustrophobia that would prevent brain fMRI testing\n  * Metal-containing intrauterine device (IUD) that would prevent fMRI testing\n  * Doubtful or unwilling to complete all study procedures (including drinking alcohol; drinking plain tap water, blood tests, 24-hour urine collection, fMRI scans, and stable isotope tests)\n  * Unwilling to be randomly assigned to intervention or control\n  * Incomplete baseline data in Weeks 1-4 (including blood tests, 24-hour urine collection, and MRI scans).","19 Years","29 Years",{"count":51,"type":22},120,"INTERVENTIONAL",[54],"NA","Social relevance:\n\nFor 30 years, people have been confused about how much plain water to drink. Over 30 years, health professionals have criticized media advice to drink 8 glasses of water per day, citing lack of evidence (Valtin et al, 2002; Yamada et al, 2022). Health authorities have not set drinking water-specific recommendations, assuming 1) that any or all types of drinks hydrate equivalently, i.e. that people do not need to drink plain water to replace lost body water, and 2) the average healthy person can rely on thirst as guide for water intake.\n\nThe lack of drinking water-specific recommendations significantly impacts daily lives because it translates into limited or no support for drinking water in public health services, laws, and retail options.\n\nScientific relevance:\n\nThirst is considered the primary driver of water intake and main defense against body water deficit in healthy young adults (IOM, 2005). Health authorities set total water intake recommendations for the average healthy man and woman (e.g. 2.5 L\u002Fd for men and 2.0 L\u002Fd for women in Europe) but, additionally, advise people to use thirst as a guide for water intake, recognizing that individual water requirements vary widely (EFSA, 2010; IOM, 2005).\n\nAlthough thirst can be satiated by water intake, it can also be ignored per custom (Greenleaf, 1992) or suppressed by an upward-shifted thirst threshold. The thirst threshold, the set-point where osmoreceptor cells shrink and release their neural or hormonal signal, is a function of the solute concentration or osmolality inside and outside the osmoreceptor cells (Nose et al, 1988a,b). Cells with higher intracellular solute content require a higher external osmolality to shrink.\n\nSpecific Aims The ultimate goal of this study is to address gaps in the literature about drinking water and check assumptions that limit the development of drinking water-specific recommendations. The study will examine if osmoadaptation to chronic hypertonicity, due to daily intake of hypertonic fluid sources, can explain suppressed thirst in healthy individuals under conditions of daily life. To facilitate causal inference about drinking water effects for long-term health, this study was designed to link experimental data about osmoadaptation at the cellular level with clinical data relevant for conditions of daily life in Salzburg Austria with population-based data about water intake and chronic disease risk in Salzburg Austria.\n\nThis study will test effects of drinking enough plain water to dilute urine everyday for 4 weeks (about 500 mL 4 times per day in summer). The study will include healthy, normal weight, young, men and women, who all usually meet European adequate intake recommendations for total water intake (TWI), but usually consume less than 1L\u002Fd PWI, and have biomarkers of chronic hypertonic stress (concentrated urine and saliva) for 4 consecutive weeks before starting the randomized study.",[57,58,59,60,61,26,62,63,64],"Chronic Underhydration","Thirst; Due to Deprivation of Water","Aestivation Metabolism","Warburg Effect","Osmoadaptation","Protein Breakdown","Brain Function","Healthy",[66,67,68,69,70,71,72],"Randomized clinical trial","Drinking water","Metabolomics","Zinc isotope","Amino acid tracing (13C,15N-glycine)","Deuterium elimination","Oura ring","2026-03-05",{"date":75,"type":31},"2026-03-11",{"date":77,"type":22},"2026-05-01",{"date":79,"type":22},"2027-12-31",{"name":81,"class":38},"Jodi Stookey",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":107,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100460586","brain-health-in-youth-with-normal-weight-overweight-and-obesity-at-risk-for-type-2-diabetes-t2d-100460586","NCT05277558","Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)","Brain Health Across the Metabolic Continuum in Youth at Risk for Type 2 Diabetes (T2D)","Metabrain","Inclusion Criteria:\n\n* 12-17 yrs. old at visit 1, 12-19 yrs. old at visit 2, Tanner II or above (determined through an exam by a pediatric endocrinologist or certified nurse practitioner trained in pediatric endocrinology), otherwise healthy except for obesity, \\\u003C450 lbs. (due to MRI scanner limits), able and willing to lie flat within the MRI scanner and do cognitive testing, fluent in English.\n\nExclusion Criteria:\n\n* Syndromic obesity, history of bariatric surgery, insulin treatment (metformin allowed if \\\u003C 6 months) for T2D, contraindications for MRI (metal, claustrophobia), braces, pregnant (pregnancy test will be done on post-menarchal girls) or breastfeeding, inability to participate in cognitive testing due to sensory or language issues, intellectual disability, special education, pharmacologic treatment for Attention Deficit Hyperactivity Disorder (ADHD), prematurity (\\\u003C36 weeks gestation), complications at birth, neurologic co-morbidities (e.g., seizures, stroke, head injury with \\>10 min loss of consciousness), significant psychiatric disorders (e.g., schizophrenia, bipolar disorder, current major depression), taking psychoactive medications (e.g., antipsychotics) that would interfere with testing or reporting illegal drug use. Self-reported smoking and alcohol use and length of time with obesity will be assessed by history (although these measures may not be fully reliable).",true,"12 Years","17 Years",{"count":94,"type":22},117,"Investigators propose to study youth across the spectrum of body mass index (BMI) and dysglycemia. This approach will allow investigators to disentangle the relationship of key features of type 2 diabetes (T2D) risk (e.g. obesity) with intermediary physiologic changes (e.g. insulin resistance, inflammation, β-cell dysfunction and dysglycemia) that pose a risk for the brain. Investigators will determine which of these factors are most associated with differences in brain structure and function among groups, over time, and how these effects differ from normal neurodevelopment.",[97,98,26,99,100,101,102,103,104,105,106],"Type2 Diabetes","Type 2 Diabetes Mellitus in Obese","Microvascular Complications","Brain Structure","Obesity, Childhood","Diabetes in Adolescence","Inflammation","Insulin Resistance","Overweight, Childhood","Cognitive Decline",[108],"Brain, Health, Youth, Type 2 Diabetes Mellitus, overweight, obesity","RECRUITING","2025-12-16",{"date":112,"type":31},"2025-12-18",{"date":114,"type":31},"2022-05-24",{"date":116,"type":22},"2027-10-31",{"name":118,"class":38},"Washington University School of Medicine",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":52,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":119},"100613223","effect-of-a-food-supplement-on-blood-glucose-levels-in-patients-with-impaired-glucose-values-100613223","NCT07263789","Effect of a Food Supplement on Blood Glucose Levels in Patients With Impaired Glucose Values","Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Euglycem in Reducing Blood Glucose in Patients With Dysglycemia After Three Months of Treatment - EUGLYCARE Study","EUGLYCARE","Inclusion Criteria:\n\n* BMI ≤30 kg\u002Fm2\n* subjects able to understand the informed consent and sign it before enrollment in the study\n* subjects willing to follow all study requirements and perform all study visits as well as collaborate with the investigator.\n\nExclusion Criteria:\n\n* ongoing treatment with drugs that can affect blood glucose\n* current participation in another investigational drug or investigational device trial or inclusion in another investigational drug or investigational device trial within the previous month",{"count":129,"type":22},108,[54],"The primary objective is to evaluate the efficacy of Euglycem® plus recommended standard diet on reducing FPG compared to baseline and to recommended standard diet alone after 3 months",[26],"2025-11-23",{"date":135,"type":31},"2025-12-04",{"date":137,"type":31},"2025-04-08",{"date":139,"type":22},"2026-01-31",{"name":141,"class":38},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":90,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":23,"phases":4,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":39},"100412961","polish-registry-of-diabetes-polred-100412961","NCT04657367","Polish Registry of Diabetes (PolReD)","Polish Registry of Diabetes - PL: Polski Rejestr Diabetologiczny (PolReD)","PolReD","Inclusion Criteria:\n\n* patients with diagnosed diabetes (according to the American Diabetes Association criteria) - diabetes group\n* patients with diagnosed prediabetes (IFG and\u002For IGT) - prediabetes group\n* patients with normoglycemia (NFG and NGT) - normoglycemia group\n* informed consent\n\nExclusion Criteria:\n\n* drug addiction\n* severe psychiatric disorders\n* patients with gestational diabetes mellitus\n* patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions",{"count":151,"type":22},10000,"10 Years","The aim of this project is to create a registry of diabetic patients, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.\n\nThe study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.",[155,156,157,26],"Diabetes","Obesity","PreDiabetes",[159,160],"diabetes registry","prediabetes registry","2025-03-21",{"date":163,"type":31},"2025-03-26",{"date":165,"type":31},"2020-02-03",{"date":167,"type":22},"2030-12-31",{"name":169,"class":38},"Medical University of Bialystok"]